WHO technical advisory group to discuss Covaxin EUL on October 26

Published On 2021-10-18 07:36 GMT | Update On 2021-10-18 07:36 GMT

Hyderabad: The technical advisory group of the World Health Organisation (WHO) will meet on October 26 to consider emergency use listing for Bharat Biotech's COVID-19 vaccine Covaxin, tweeted Soumya Swaminathan, chief scientist of the global health body, on Sunday.

"The technical advisory group will meet on Oct 26th to consider EUL for #Covaxin. @WHO has been working closely with @BharatBiotech to complete the dossier. Our goal is to have a broad portfolio of vaccines approved for emergency use & to expand access to populations everywhere," she tweeted.

The Strategic Advisory Group of Experts on Immunization (SAGE) of the WHO which held a meeting on October 6 to make its recommendations on Covaxin on EUL, among other issues, had earlier said it will take a call on granting EUL status to Covaxin in a week time.

The EUL process being carried out by the WHO and the Technical Advisory Group of independent experts - is centered on determining if a manufactured product such as vaccine is quality-assured, safe and effective, WHO earlier said.

"The WHO is currently reviewing the data submitted by the vaccine maker and the date for a decision on the jab is "October 2021" according to the update available on the WHO website," reports PTI.

Covaxin is one of the three vaccines that have received emergency use authorisation from India's drug regulator and is being used in the nationwide inoculation programme, along with Covishield and Sputnik V.

The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.

The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

Article Source : with agency inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

WHO technical advisory group to discuss Covaxin EUL on October 26

Similar News

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

CBI Cracks Down on PCI Chief Montu Patel in College Bribery Scandal